Tokyo - Delayed Quote JPY

Nxera Pharma Co., Ltd. (4565.T)

Compare
1,231.00 +26.00 (+2.16%)
At close: 3:15 PM GMT+9
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 4565.T

Recent News: 4565.T

View More
Nxera Pharma to Host R&D Day 2024

Nxera Pharma to Host R&D Day 2024
Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan

Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ? in Japan

Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ? in Japan
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia

Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO

Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024

Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results

Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone

Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
View More

Related Tickers